Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sb-649868. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 known ✓ | O43613 | 20/20 | 1.00 |
| ▸ | HCRTR2 known ✓ | O43614 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-649868 SCHEMBL8045969 | 1.00 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL1398620 | 0.95 | HCRTR1 (0.90) | HCRTR1HCRTR2 | |
| SCHEMBL1398677 | 0.95 | HCRTR1 (0.90) | HCRTR1HCRTR2 | |
| SCHEMBL1398707 | 0.95 | HCRTR1 (0.90) | HCRTR1HCRTR2 | |
| SCHEMBL3638954 | 0.91 | HCRTR1 (0.83) | HCRTR1HCRTR2 | |
| SCHEMBL20827765 | 0.90 | HCRTR1 (0.81) | HCRTR1HCRTR2 | |
| SCHEMBL15173819 | 0.88 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL18734312 | 0.88 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL15173821 | 0.88 | HCRTR1 (1.00) | HCRTR1HCRTR2 | |
| SCHEMBL15174162 | 0.88 | HCRTR1 (1.00) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977993-A | Solid forms of thienopyrimidinedione ACC inhibitors and methods of making the same | 吉利德阿波罗公司 | 2025-05-13 | — | — | CN | disclosed |
| WO-2025015283-A1 | OPIOID USE DISORDER COMBINATION TREATMENTS | THE PENN STATE RESEARCH FOUNDATION (US) | 2025-01-16 | — | — | WO | disclosed |
| US-20240197704-A1 | TREATMENT METHODS AND COMPOSITIONS COMPRISING PERAMPANEL | UNIV JOHNS HOPKINS (US) | 2024-06-20 | — | — | US | disclosed |
| EP-4364795-A2 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | Gilead Apollo, LLC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-11963961-B2 | Combination therapy comprising an ACC inhibitor | GILEAD SCIENCES, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | GILEAD APOLLO, LLC (US) | 2024-02-27 | — | — | US | disclosed |
| EP-3423456-B1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | GILEAD APOLLO LLC (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-4273132-A2 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | Gilead Sciences, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3589636-B1 | PROCESSES FOR PREPARING ACC INHIBITORS AND SOLID FORMS THEREOF | GILEAD SCIENCES INC (US) | 2023-09-13 | — | — | EP | disclosed |
| CN-115449529-A | Process for preparing ACC inhibitors and solid forms thereof | 吉利德科学公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-110382503-B | Process for preparing ACC inhibitors and solid forms thereof | 吉利德科学公司 | 2022-07-19 | — | — | CN | disclosed |
| US-11279710-B2 | Processes for preparing ACC inhibitors and solid forms thereof | GILEAD SCIENCES, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20220064181-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | GILEAD APOLLO, LLC | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912718-B2 | Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof | ACACA, ACACB, COASY | HCRTR1 3877/4885HCRTR2 3984/4885 |
| US-11963961-B2 | Combination therapy comprising an ACC inhibitor | ACACB, ACACA, LIPC | HCRTR1 2556/4885HCRTR2 1738/4885 |
| US-11279710-B2 | Processes for preparing ACC inhibitors and solid forms thereof | ACACA, ACACB, ACAT2 | HCRTR1 3564/4885HCRTR2 4127/4885 |
| US-20220064181-A1 | SOLID FORMS OF A THIENOPYRIMIDINEDIONE ACC INHIBITOR AND METHODS FOR PRODUCTION THEREOF | ACACA, ACACB, COASY | HCRTR1 3877/4885HCRTR2 3984/4885 |
| US-20240197704-A1 | TREATMENT METHODS AND COMPOSITIONS COMPRISING PERAMPANEL | SYNGR2, CNTN1, MECP2 | HCRTR1 161/4885HCRTR2 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.